Register for our free email digests:
Kadmon gets exclusive rights to Dyax's MMP-14 inhibitor for cancer
- Large Molecule
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.